StreetAlpha.app
Home › Stocks › NVAX

Novavax Inc (NVAX)

Healthcare
$7.96
▼ −1.24%
LAST CLOSE · NOV 17

Novavax develops vaccines and licenses its Matrix-M adjuvant to drug makers and governments worldwide. It last closed at $7.96 on Nov 17, down 1.24% on the day. The average 12-month price target from 2 analysts is $12.00 (+50.8% from the last close), with a high of $16.00 and a low of $8.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in NVAX, 0% of them bullish and 100% bearish.

AI Auto Pilots
Is NVAX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$411.6M
−61.3% vs a year ago
Net income
−$76.7M
−122.5% vs a year ago
EPS (diluted)
−$0.52
−125.9% vs a year ago
Gross margin
78.0%
$321.1M gross profit
Valuation
Market cap
$1.3B
165.0M shares
P/E
–
No P/E while losing money
Price to sales
3.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$222.5M
At Sep 30
Debt
$292.1M
At Sep 30
Shareholder equity
−$216.9M
Shares outstanding
165.0M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.1B$1.1BFY2021FY2022: $2.0B$2.0BFY2022FY2023: $983.7M$983.7MFY2023FY2024: $682.2M$682.2MFY2024FY2025: $1.1B$1.1BFY2025

From NVAX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Sell
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Sell
2firms
1 Buy0 Hold1 Sell
Only 2 firms rated NVAX in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 50.8% upside

Based on 2 analysts who set a price target on NVAX in the past 90 days. The average target is $12.00, with a high of $16.00 and a low of $8.00, compared with the last close of $7.96.

$7$10$13$17PAST 66 TRADING DAYS12-MONTH TARGETSHIGH $16AVG $12LOW $8May 22LAST CLOSE+12 MO$7$10$13$17PAST 66 DAYSTARGETSHIGH $16AVG $12LOW $8May 22LAST CLOSE+12 MO
Highest target$16.00
Average target$12.00
Lowest target$8.00
Latest rating changes
B. Riley SecuritiesReiterated
Nov 6Buy$16
CitigroupMaintained
Oct 15Sell$8
DateFirmActionRatingPrice target
Nov 6B. Riley SecuritiesReiteratedBuy$16
Oct 15CitigroupMaintainedSell$8
Loading…

Technical Analysis

NVAX · as of the Nov 17 close · updated after every close
Turning down, nearing oversold

The stock is 23% below its 20 day and 31% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $7.85, and the nearest resistance the Pivot at $7.99.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.0%/day
Key levels
$13.3952 week high+68.2%
$10.4550 day average+31.3%
$9.7920 day average+23.0%
$9.53100 day average+19.7%
$9.33200 day average+17.2%
$8.11Pivot R1+1.9%
$8.09Swing high (Aug 7)+1.6%
$7.99Pivot+0.4%
$7.96Last close
$7.85Pivot S1−1.4%
$7.84Swing low (Aug 18)−1.5%
$6.2052 week low−22.1%
Indicators
RSI (14)34.74Weak, oversold below 30Neutral
MACD-0.58Below its signal lineBearish
Stochastic3.7Near the bottom of its rangeOversold
ADX (14)26.1Trending down
Williams %R-97.6Oversold below −80, overbought above −20Oversold
CCI (20)-197.7Oversold below −100, overbought above 100Oversold
Rate of change−17.8%Change over 10 sessionsBearish
ATR (14)$0.79Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NVAX

What happened before

See how NVAX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NVAX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NVAX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 5 – Oct 5
Loading…

See today’s whale options flow across the market →

NVAX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼104 buying vs 125 selling
  • ▲Held by funds +1.6 pts
  • ▼Funds holding -10
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 2.92 to 4.34
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding261271−3.7%
In funds' top 1032+50.0%
Held by funds72.8%71.2%+1.6 pts
New / increased30 / 7440 / 76−10.3%
Reduced / sold out85 / 4088 / 32+4.2%
Put/call ratio4.342.92+48.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NVAX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NVAX is in one of them and how their past NVAX trades turned out.

NVAX in the AI portfolios
Loading…

NVAX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NVAX in an article yet. Here's the latest on the wider market.

NVAX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 5
Who traded NVAX · since 2020
Latest 0 filings of 2
PersonTypeAmountTradedFiledDelay

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Novavax

Novavax is a vaccine company based in Gaithersburg, Maryland. It develops vaccines using a platform built on protein nanoparticles, and its COVID-19 vaccine, Nuvaxovid, is sold with Sanofi leading commercialization. The company also licenses its Matrix-M adjuvant, which helps vaccines produce a stronger immune response, to partners such as the Serum Institute of India and other drug makers. Its customers include national governments and global pharmaceutical companies.

Headquarters
Gaithersburg, MD
Founded
1987